Skip to main content
NanoVibronix, Inc. logo

NanoVibronix, Inc. — Investor Relations & Filings

Ticker · NAOV ISIN · US63008J7028 LEI · 5493008114LTFZQ2I595 US Manufacturing
Open in API
Filings indexed 512 across all filing types
Latest filing 2023-01-18 Regulatory Filings
Country US United States of America
Listing US NAOV

About NanoVibronix, Inc.

https://nanovibronix.com/

NanoVibronix, Inc. is a medical technology company that develops non-invasive and minimally invasive biological response-activating devices. The company's core technology is based on a proprietary, patented low-intensity surface acoustic wave (SAW) ultrasound. Its main products include PainShield®, a portable device for pain therapy and the treatment of nerve and soft tissue damage, and UroShield®, an ultrasound device designed to prevent bacterial biofilm on urinary catheters. These prescription-based products offer therapeutic alternatives to medication for pain management, wound healing, and biofilm prevention, targeting both clinical and home care settings.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2023
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The text mentions Item 7.01 Regulation FD Disclosure and includes a press release about the company's product update. There are no financial statements or detailed financial data included, only a press release is attached as Exhibit 99.1. The document length is under 5,000 characters and it primarily serves as an announcement of an event rather than a full financial report or detailed filing. Therefore, it fits the category of Regulatory Filings (RNS), which is the fallback for miscellaneous filings that do not fit other categories and includes Form 8-K filings that are not earnings releases or other specific reports.
2023-01-18 English
Director's Dealing 2023
Director's Dealing
2023-01-05 English
Declaration of Voting Results & Voting Rights Announcements 2022
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. It reports on the results of the company's 2022 Annual Meeting of stockholders, including voting results on various proposals such as election of directors, amendments to the certificate of incorporation, and approval of amendments to the long-term incentive plan. The document also includes information about the submission of matters to a vote of security holders and a press release about the meeting results. The key content is the official results from shareholder votes at the Annual Meeting, which aligns with the category 'Declaration of Voting Results & Voting Rights Announcements (DVA)'. The document is not an annual report, earnings release, or proxy statement itself, but a current report disclosing voting outcomes. Therefore, the appropriate classification is DVA with high confidence.
2022-12-15 English
Capital/Financing Update 2022
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes a securities purchase agreement for a registered direct offering of common stock, including details about the offering, placement agent fees, and warrants. It also references exhibits such as the purchase agreement and legal opinion. There are no financial statements or comprehensive financial data typical of an Annual Report (10-K) or Interim Report (IR). The document is primarily an announcement of a capital raising transaction and related agreements, fitting the category of Capital/Financing Update (CAP). The length (7300 characters) and detailed transaction description support this classification rather than a brief announcement or regulatory filing. Therefore, the filing type is CAP with high confidence.
2022-12-01 English
Capital/Financing Update 2022
Capital/Financing Update Classification · 100% confidence The document is a Form 424B5 prospectus supplement filed pursuant to Rule 424(b)(5) under the Securities Act. It details an offering of 4,800,000 shares of common stock by NanoVibronix, Inc., including pricing, placement agent fees, use of proceeds, risk factors, and other offering-related information. The document is a registration statement supplement related to a securities offering, not a financial report, earnings release, or management discussion. It is a capital raising disclosure document describing the terms and conditions of a stock offering. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering terms, confirming it is not merely an announcement or a brief notice but a full prospectus supplement related to financing.
2022-11-30 English
Regulatory Filings 2022
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The text mentions an event dated November 28, 2022, specifically the FDA 510(k) clearance of a product, and includes a press release as an exhibit. There are no financial statements or detailed financial data presented, and the document is relatively short (3234 characters). This fits the profile of a Regulatory Filing (RNS) rather than a full financial report or other specific filing types. The Form 8-K is a general regulatory announcement category.
2022-11-29 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.